Listed

SenesTech, Inc.: Form 10-Q for the period ended Mar 31, 2020

Filed with the SEC on May 15, 2020 and accepted by EDGAR at May 15, 2020, 16:18 ET.

Share

Management's discussion and analysis

As filed, 35,917 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As used in this Quarterly Report on Form 10-Q, “SenesTech,” the “Company,” “we,” “us,” or “our” refer to SenesTech, Inc., a Delaware corporation.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our condensed consolidated financial statements and related notes.

Forward-Looking Statements

Some statements and information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, notes to our condensed consolidated financial statements and elsewhere in this report are not historical facts but are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, readers can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology, which when used are meant to signify the statement as forward-looking. These forward-looking statements include, but are not limited to:

  • The impacts and implications of the COIVD-19 pandemic;
  • Our commercialization and promotion strategy and plans, including key elements to our business strategy, how we commercialize, our sales approach, our areas and markets of focus, our pricing strategy, our strategic relationships and which geographic markets we target;
  • The potential market opportunities for commercializing our product candidates and the role we expect ContraPest to hold within the market;
  • Our seeking, obtaining or maintaining regulatory approvals for our product candidates;
  • The anticipated results and effects of our products, including those indicated in studies;
  • Our expectations regarding the potential market size for our products and how the market may develop;
  • Our estimates or expectations related to our revenue, cash flow, expenses, capital requirements and need for additional financing;
  • Our ability to improve our cost structure and gross margins, and limit our cash burn;
  • Our plans for our business, including for research and development;
  • Our ability to enter into strategic arrangements and to achieve the expected results from such arrangements;
  • The initiation, timing, progress and results of field studies and other studies and trials and our research and development programs;
  • Our ability to develop and manufacture our products candidates to meet demand and in a commercially efficient manner;
  • The scope of protection we are able to obtain and maintain for our intellectual property rights covering our product candidates;
  • Our financial performance, including our ability to fund operations;
  • Developments and projections relating to our projects, competitors and our industry;
  • Our expectation regarding our ability to sell our products at commercially reasonable values;
  • Our beliefs and expectations related to pending litigation; and
  • Other risks and uncertainties, including those described or incorporated by reference under the caption “Risk Factors” in our 2019 Annual Report.

These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our own, or our industry’s actual results, to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Item 1A of Part II of our Annual Report on Form 10-K, as amended by Form 10-K/A, for the year ended December 31, 2019, filed with the SEC on March 17, 2020 and April 21, 2020, respectively, (collectively, the “2019 Annual Report”), and Item 1A of Part II of this Form 10-Q, in each case entitled “Risk Factors,” and those contained from time to time in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Overview

Since our inception, we have sustained significant operating losses in the course of our research and development activities and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to prepare and launch commercialization of our first product, ContraPest. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock.

We have also raised capital through debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.

Through March 31, 2020, we had received net proceeds of $68.9 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.6 million in net product sales. At March 31, 2020, we had an accumulated deficit of $98.6 million and cash and cash equivalents of $1.5 million.

We have incurred significant operating losses every year since our inception. Our net losses were $2.7 million for the three months ended March 31, 2020 and $2.4 million for the three months ended March 31, 2019. We expect to continue to incur significant expenses and generate operating losses for at least the next 12 months.

We have historically utilized, and intend to continue to utilize, various forms of stock-based awards in order to hire, retain and motivate talented employees, consultants and directors and encourage them to devote their best efforts to our business and financial success. In addition, we believe that our ability to grant stock-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders.

As a result, a significant portion of our operating expenses includes stock-based compensation expense. Stock-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. Specifically, our stock-based compensation expense for the three months ended March 31, 2020 and March 31, 2019 was $151,000 and $252,000, respectively, which represented 6.4% and 10.6%, respectively, of our total operating expenses for those periods.

We will need additional funding in order to continue to fund our operations and achieve profitability and become cash flow positive and will continue to seek additional financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations.

While the effects of the COVID-19 pandemic did not have a significant impact on revenue during our first quarter, the travel and other restrictions that started in March resulted in a significant slowdown in our proof of concept field studies and sales efforts. We were able to resume field studies in some important projects by late-April and initially believed that we would re-start all our most significant field studies as we obtained limited waivers of certain travel bans; however, we still have delays on certain projects that might remain on hold until the lifting of government restrictions. These delays could impact our results in future quarters. Initially, we believed that pest control would continue through the pandemic as a necessity and we were and have been able to maintain our manufacturing with cautionary, best practices put in place. However, we have concerns over distributor, pest control operator and individual consumer spending as restrictive measures related to the pandemic continue. Stay at home orders across the world have impeded our ability to communicate with current and prospective customers, potentially reducing sales until the orders are lifted. In addition, federal, state and municipal budgets are under severe strain as a result of the pandemic. This may delay or impede their ability to make near term purchases of our products. While we have stocked certain long lead time inventory raw material ingredients, any prolonged impact on the suppliers we rely on for the purchase of these items by the COVID-19 pandemic could impact future manufacturing operations.

Components of our Results of Operations

Net Sales

Net sales are comprised primarily of sales, net of discounts and promotions, of ContraPest and related components, to our distributors and customers.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the research and development of ContraPest and our other product candidates, which include:

  • Employee related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
  • Expenses incurred in connection with the development of our product candidates; and
  • Facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies.

We expense research and development costs as incurred.

We continue to investigate other applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates. At this time, we cannot reasonably estimate the costs for further development of ContraPest or the cost associated with the development of any of our other product candidates.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, sales, marketing and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.

We continue to focus on improving our cost structure, with the goals of shifting resources to commercialization, significantly reducing our year over year burn rate and achieving a 50% or greater gross margin. Steps have included relocating to more cost-efficient space, organizational restructuring, and improving our manufacturing and supply processes and reducing staffing. We expect to see the benefit to costs of these steps in the coming quarters.

We plan to continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our selling, general and administrative expenses for the foreseeable future.

Interest Income

Interest income consists primarily of interest income earned on cash and cash equivalents.

Interest Expense

Interest expense consists primarily of interest accrued on our finance lease and note commitments.

Other Income (Expense), Net

Other income (expense), net, consists primarily of recognized change in value of short-term investments and income (expense) related to the year-over-year fair market value adjustment of our derivative warrant.

Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial statement and tax bases of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate has been affected by the full valuation allowance recorded since inception on the Company’s deferred tax assets.

Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net operating losses we have incurred in each year in our history or for our generated research and development tax credits, due to the uncertainty regarding our ability to realize a benefit from these tax attributes. At March 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $61.3 million and $47.8 million, respectively, not considering any potential IRC Section 382 annual limitation discussed below. The federal loss carryforwards begin to expire in 2023, unless previously utilized. Included in the $61.3 million of federal loss carryforwards are approximately $16.8 million of net operating losses that do not expire due to the tax law changes promulgated in conjunction with the Tax Cuts and Jobs Act of 2017.

Additionally, the utilization of the net operating loss and tax credit carryforwards could be subject to annual limitations under sections 382 and 383 of the Internal Revenue Code of 1986, and similar state tax provisions, due to ownership change limitations that may have occurred previously or that could occur in the future. These ownership changes limit the amount of net operating loss carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by section 382, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percent points over a three-year period. The Company has not conducted an analysis of an ownership change under section 382. To the extent that a study is completed and an ownership change is deemed to have occurred, the Company’s net operating losses could be limited.

Comparison of the Three Months Ended March 31, 2020 and 2019

The following table summarizes our results of operations for the three months ended March 31, 2020 and 2019:

Revenue: For the Three Months Ended March 31, 2020 2019
Sales $37 $19
Cost of sales 22 12
Gross profit 15 7
Operating expenses:
Research and development 296 464
Selling, general and administrative 2,045 1,904
Total operating expenses 2,341 2,368
Net operating loss (2,326) (2,361)
Other income (expense):
Interest income 2 15
Interest expense (8) (13)
Other income 15 (5)
Total other income (expense) 9 (3)
Net loss and comprehensive loss (2,317) (2,364)
Deemed dividend-warrant price protection-revaluation adjustment 414 -
Net loss attributable to common shareholders $(2,731) $(2,364)
Weighted average common shares outstanding - basic and fully diluted 1,611,304 1,175,920
Net loss per common share - basic and fully diluted $(1.69) $(2.01)

Net Sales

Net sales were $37,000 for the three months ended March 31, 2020, compared to $19,000 for the three months ended March 31, 2019. Sales increased $18,000 due to our shift to pull through sales strategy directed at consumers and end users. This strategy has shown initial promise. However, the benefit of this strategy has been offset by reduced sales, reflecting reduced spending by customers due to COVID-19.

Cost of Sales

Cost of sales was $22,000 or 59.5% of net sales for the three months ended March 31, 2020, compared to $12,000 or 63.2% for the three months ended March 31, 2019. The increase in cost of goods sold of $10,000 in 2020 is primarily due to higher sales volume. The decrease in cost of sales as a % of net sales was due to reduced scrap expense and continued process improvement and efficiencies. We anticipate cost of goods sold as a percentage of sales will improve for the foreseeable future due to manufacturing efficiencies as a result of the scale up activities.

Gross Profit

Gross profit for the three months ended March 31, 2020 was $15,000 or 40.5% of net sales, compared to a gross profit of $7,000 or 39.0% of net sales, for the same period in 2019. The increase in gross profit was a direct result of decreased scrap related to scale-up activities as well as continued process improvement and efficiencies.

Research and Development Expenses

(in thousands)

Direct research and development expenses: Unallocated expenses: Three Months Ended March 31, 2020 2019 Increase (Decrease)
Personnel related (including stock-based compensation) $137 $226 $(89)
Facility-related 42 63 (21)
Other 117 175 (58)
Total research and development expenses $296 $464 $(168)

Research and development expenses were $296,000 for the three months ended March 31, 2020, compared to $464,000 for the same period in 2019. The $168,000 decrease in research and development expenses was primarily due to a decrease of $89,000 in personnel-related costs, including stock-based compensation expense, due to the classification of certain field support employees to sales and marketing. With more focus on the commercialization of ContraPest, it was determined that these certain field support employees previously classified as research and development are now refocused on sales and marketing efforts.

Facility-related expense decreased $21,000 due primarily to the cancellation of a facility lease of 1,954 square feet of research and development space in Flagstaff, Arizona.

The decrease in other research and development expenses of $58,000 was primarily due to a reclassification of other expenses related to certain field support employees to sales and marketing as described above.

We also continue to develop our supply chain, particularly identifying and improving our sourcing key ingredients for our product candidates.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $2.0 million for the three months ended March 31, 2020, as compared to approximately $1.9 million for the three months ended March 31, 2019. The increase of $100,000 in selling, general and administrative expenses was primarily due to a decrease of $100,000 in net salary costs, a decrease of $30,000 in travel expenses, offset by a $165,000 increase in professional service fees and $65,000 in expenses related to restricted use field projects. The decrease in net salary costs of $100,000 was due primarily to a decrease of stock compensation expenses. The increase in professional services expenses was primarily due to increased legal expenses related to litigation settlement and the 1-for-20 reverse stock split and common stock offerings.

Interest Income/Expense, Net

We recorded interest expense of $6,000, net, for the three months ended March 31, 2020, as compared to interest income, net, of $2,000 for the same period in 2019. The $8,000 decrease in interest income was a result of decreased interest income earned as a result of lower average daily cash balance and year over year.

Other Income (Expense)

We recorded $15,000 of other income, net, for the three months ended March 31, 2020, compared to $5,000 of other expense, net, for the same period in 2019. The $20,000 net increase is due primarily to recognized gains of $15,000 during the three months ended March 31, 2020 and a decrease in other expenses related to the year-over-year fair market value adjustment of our derivative warrant.

Liquidity and Capital Resources

Since our inception, we have sustained significant operating losses in the course of our research and development activities and commercialization efforts and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. We have funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock; debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees.

Through March 31, 2020, we had received net proceeds of $68.9 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, and an aggregate of $1.7 million from licensing fees and an aggregate of $0.6 million from product sales. At March 31, 2020, we had an accumulated deficit of $98.6 million and cash and cash equivalents of $1.5 million.

Our ultimate success depends upon the outcome of a combination of factors, including: (i) successful commercialization of ContraPest and maintaining and obtaining regulatory approval of our products and product candidates; (ii) market acceptance, commercial viability and profitability of ContraPest and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs.

We will need additional funding in order to continue to fund our operations and achieve profitability and become cash flow positive and will continue to seek additional financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations.

Additional Funding Requirements

We expect our expenses to continue or increase in connection with our ongoing activities, particularly as we focus on marketing and sales of ContraPest. Further, the COVID-19 pandemic will likely delay completion of field studies and achievement of sales, which will further increase our need for financing. In addition, we will continue to incur costs associated with operating as a public company.

In particular, we expect to incur substantial and increased expenses as we:

  • Change our work processes to address COVID-19 workplace changes;
  • Work to maximize market acceptance for, and generate sales of, our products;
  • Manage the infrastructure for the sales, marketing and distribution of ContraPest and any other product candidates for which we may receive regulatory approval;
  • Continue the development of ContraPest and our other product candidates, including engaging in any necessary field studies;
  • Seek additional regulatory approvals for ContraPest and our other product candidates;
  • Scale up manufacturing processes and quantities to meet future demand of ContraPest and any other product candidates for which we receive regulatory approval;
  • Continue product development of ContraPest and advance our research and development activities and advance the research and development programs for other product candidates;
  • Maintain, expand and protect our intellectual property portfolio; and
  • Add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.

We believe we will need additional financing to fund these continuing and additional expenses.

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

Three Months Ended March 31, 2020 2019
Cash used in operating activities $(1,871) $(1,948)
Cash provided by (used in) investing activities 40 (11)
Cash provided by (used in) financing activities 1,387 (15)
Net increase (decrease) in cash and cash equivalents $(444) $(1,974)

Operating Activities.

During the three months ended March 31, 2020, operating activities used $1.9 million of cash, primarily resulting from our net loss of $2.3 million offset by changes in our operating assets and liabilities of $233,000 and by non-cash charges of $213,000, consisting primarily of stock-based compensation, depreciation and gains recognized on sale of equipment. Our net loss was primarily attributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the three months ended March 31, 2020 consisted primarily of a net increase in prepaid expenses of $40,000 offset by a net decrease in accrued expenses and accounts payable of $119,000, a decrease in accounts receivable-trade and accounts receivable-other of $127,000, a decrease in other assets of $9,000 and a decrease in inventory of $18,000.

During the three months ended March 31, 2019, operating activities used $1.9 million of cash, primarily resulting from our net loss of $2.4 million offset by changes in our operating assets and liabilities of $48,000 and by non-cash charges of $368,000, consisting primarily of stock-based compensation, depreciation and amortization. Our net loss was primarily attributable to research and development activities and our selling, general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the three months ended March 31, 2019 consisted primarily of a net increase in accrued expenses and accounts payable of $136,000 and a decrease in deposits of $1,000 offset by an increase in inventory of $74,000, an increase in receivables of $11,000, an increase in prepaid expenses of $3,000 and a decrease in deferred rent of $1,000.

Investing Activities.

For the three months ended March 31, 2020, we generated $40,000 in net cash related to investing activities as a result of sales of fixed assets.

For the three months ended March 31, 2019, we used $11,000 in net cash related to investing activities due to purchases of property and equipment.

Financing Activities.

During the three months ended March 31, 2020, net cash provided by financing activities was $1.4 million as a result of proceeds received from the issuance of common stock of $1.4 million offset by $34,000 related to payments of finance lease obligations and 14,000 of payments of notes payable.

During the three months ended March 31, 2019, net cash used by financing activities was $15,000 as a result of payments of $32,000 related to notes payable and $19,000 in payments of finance lease obligations, offset by proceeds from the exercise of warrants of $36,000.

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies and Significant Judgments and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — *Revenue from Contracts with Customers (“*ASC 606”). Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — *Revenue Recognition (“*ASC 605”). Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of the fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The performance obligations identified by the Company under Accounting Standards Codification (“ASC”) Topic 606, Revenue From Contracts With Customers, are straightforward and similar to the unit of account and performance obligation determination under ASC Topic 605, Revenue Recognition.

Stock-Based Compensation

We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures, in accordance with ASC Topic 718 — Stock Compensation. We estimate the grant date fair value of the awards, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these stock options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The fair value of the stock options granted to non-employees is re-measured as the stock options vest and is recognized in the statements of operations and comprehensive loss during the period the related services are rendered.

We recorded stock-based compensation expense of approximately $151,000 and $252,000 for the three months ended March 31, 2020 and 2019, respectively. We expect to continue to grant stock options and other equity-based awards in the future and continue to recognize stock-based compensation expense in future periods.

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and loss per share of common stock could have been significantly different. Our assumptions are as follows:

  • Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore, we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
  • Expected volatility. Expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.
  • Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
  • Expected dividend. The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
  • Expected forfeitures. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.

Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock

As noted above, we are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model.

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income and net income per share amounts could have been significantly different. The fair value per share of our common stock for purposes of determining stock-based compensation expense is the closing price of our common stock as reported on the applicable grant date. The compensation cost that has been included in the statements of operations and comprehensive loss for all stock-based compensation arrangements is as follows:

(in thousands)

Three Months Ended March 31, 2020 2019
Selling, general and administrative expenses $148 $243
Research and development expense 3 9
Total stock-based compensation expense $151 $252

The intrinsic value of stock options outstanding as of March 31, 2020 was $0.

Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we intend to comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

Controls and procedures

As filed, 1,576 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We conducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act), under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e)) as of the end of the period covered by this report.

These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to management, including the principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 2,547 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except as discussed below, there have been no material changes in the risk factors set forth in Part I, Item 1A, “Risk Factors” in our 2019 Annual Report.

The impacts of the coronavirus pandemic could adversely affect our business, and other similar crises could result in similar or other harms.

The outbreak of the novel coronavirus (COVID-19) pandemic has resulted in widespread travel and transportation restrictions and closures of commercial spaces, industrial facilities and other spaces and businesses in and across the United States and the world, including in the locations we operate or target sales. As a result, our business has been impacted and we could face continued or more adverse effects. In addition, our results and financial condition may be adversely affected by federal or state legislation (or other similar laws, regulations, orders or other governmental or regulatory actions or best practices) that would impose new restrictions on our ability to operate our business or customers to operate their businesses. For example, our sales and technical field forces have been restricted from traveling, which adversely affects our ability to sell our products and complete field studies. While we have implemented cautionary procedures at our manufacturing facility, there may be disruptions to our ability to manufacture due to “stay at home” orders or additional workplace controls. Our customers may be less inclined or unable to purchase our products or continue product studies due to restrictions under which they may be operating. Those restrictions are more severe in some jurisdictions, such as California. If financial markets continue to tighten, we may have more limited ability to raise necessary financing. We source some of our critical raw materials from Asia, and the coronavirus has caused supply chain disruptions, which could limit a timely supply of materials. Each of these could have negative effects on our business, results of operations, financial condition and cash flows. Even if the coronavirus pandemic passes, another crisis with similar effects could develop and harm our business, financial results and liquidity.

The degree to which COVID-19 may impact our results of operations and financial condition is unknown at this time and will depend on future developments, including the ultimate severity and the duration of the pandemic, and further actions that may be taken by governmental authorities or businesses or individuals on their own initiatives in response to the pandemic.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-01-01 to 2020-03-31$37.0kus-gaap:Revenues
Cost of revenue3 months2020-01-01 to 2020-03-31$22.0kus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-01-01 to 2020-03-31$15.0kus-gaap:GrossProfit
Research and development3 months2020-01-01 to 2020-03-31$296.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-01-01 to 2020-03-31−$2.3mus-gaap:OperatingIncomeLoss
Net income3 months2020-01-01 to 2020-03-31−$2.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-01-01 to 2020-03-31−$1.69us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2020-01-01 to 2020-03-31−$1.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-03-31$1.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-03-31$3.0mus-gaap:AssetsCurrent
Total assetsAt period end2020-03-31$4.2mus-gaap:Assets
Current liabilitiesAt period end2020-03-31$1.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-03-31$2.2mus-gaap:Liabilities
Long-term debtAt period end2020-03-31$96.0kus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-03-31$116.0kus-gaap:LongTermDebtCurrent
Short-term borrowingsAt period end2020-03-31$116.0kus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2020-03-31$2.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-20-012605. Last ingested by Listed: Nov 14, 2026, 18:52 ET. Listed shows no prices and gives no investment advice.